Jefferies on Biocon Hold, TP Rs 360

 16 Feb 2026 09:01 AM

Jefferies on Biocon Hold, TP Rs 360

HSBC maintains buy on Biocon; Cuts target price to ₹445 from ₹455

 16 Feb 2026 09:02 AM

HSBC maintains buy on Biocon; Cuts target price to ₹445 from ₹455

Goldman Sachs maintains neutral on Biocon with a target price of ₹375

 16 Feb 2026 09:03 AM

Goldman Sachs maintains neutral on Biocon with a target price of ₹375

Biocon: Company Aims For Steady Growth, Better Margins, And Cash Flow-Driven Value Creation, Focusing On Improving Returns. Biocon Expects Increased Growth In Biosimilars Next Fiscal Year, With Current Year Margins Around Mid-20s And Future Margin Improvements Anticipated Without Specific Targets.

 16 Feb 2026 08:55 AM

Biocon: Company Aims For Steady Growth, Better Margins, And Cash Flow-Driven Value Creation, Focusing On Improving Returns. Biocon Expects Increased Growth In Biosimilars Next Fiscal Year, With Current Year Margins Around Mid-20s And Future Margin Improvements Anticipated Without Specific Targets.

Biocon: Expects Interest Savings Of Around INR 300 Crores Starting FY27 From Paying Off Structured Debt, With Current Net Debt Between $1.1B And $1.2B And A Debt-EBITDA Ratio Below 2.5X. The CRDMO Division Believes Challenges From A Single Customer Will Be Temporary, Maintaining Confidence In Long-Term Growth.

 16 Feb 2026 08:57 AM

Biocon: Expects Interest Savings Of Around INR 300 Crores Starting FY27 From Paying Off Structured Debt, With Current Net Debt Between $1.1B And $1.2B And A Debt-EBITDA Ratio Below 2.5X. The CRDMO Division Believes Challenges From A Single Customer Will Be Temporary, Maintaining Confidence In Long-Term Growth.

Biocon: Company Plans to Launch Semaglutide in India Through Partnerships - Concall Update.

 13 Feb 2026 10:16 AM

Biocon: Company Plans to Launch Semaglutide in India Through Partnerships - Concall Update.

BIOCON: Q3 CONS NET PROFIT 1.44B RUPEES VS 251M (YOY); EST 1.69B || Q3 REVENUE 41.7B RUPEES VS 38.2B (YOY)

 12 Feb 2026 08:08 PM

BIOCON: Q3 CONS NET PROFIT 1.44B RUPEES VS 251M (YOY); EST 1.69B || Q3 REVENUE 41.7B RUPEES VS 38.2B (YOY)

BIOCON: Q3 EBITDA 8.3B RUPEES VS 770M (YOY) || Q3 EBITDA MARGIN 19.97% VS 19.67% (YOY)

 12 Feb 2026 08:09 PM

BIOCON: Q3 EBITDA 8.3B RUPEES VS 770M (YOY) || Q3 EBITDA MARGIN 19.97% VS 19.67% (YOY)

Biocon: Fitch Changes Biocon Biologics Outlook To Positive And Confirms IDR At 'BB-'

 06 Feb 2026 12:44 PM

Biocon: Fitch Changes Biocon Biologics Outlook To Positive And Confirms IDR At 'BB-'

Biocon: Company Gets VAI Status From US FDA For Andhra Pradesh Plant After Inspection From November 3 To 7, 2025

 28 Jan 2026 06:38 PM

Biocon: Company Gets VAI Status From US FDA For Andhra Pradesh Plant After Inspection From November 3 To 7, 2025

Biocon: Company Achieves 98% Ownership In Biocon Biologics' Equity Shares

 21 Jan 2026 08:03 PM

Biocon: Company Achieves 98% Ownership In Biocon Biologics' Equity Shares

Biocon: Co QIP of $460M or Rupees 41.6B || SBI, ICICI Funds Lead

 13 Jan 2026 11:38 AM

Biocon: Co QIP of $460M or Rupees 41.6B || SBI, ICICI Funds Lead

Biocon: Sets Floor Price At 387.74 Rupees For Each Share

 12 Jan 2026 05:56 PM

Biocon: Sets Floor Price At 387.74 Rupees For Each Share

Biocon: Gets USFDA Green Light For Everolimus Tablets In 2MG, 3MG, And 5MG For Treating Tuberous Sclerosis Complex And SEGAs.

 12 Jan 2026 08:45 AM

Biocon: Gets USFDA Green Light For Everolimus Tablets In 2MG, 3MG, And 5MG For Treating Tuberous Sclerosis Complex And SEGAs.

Biocon: Biocon Biologics Aims To Grow Its Biosimilar Oncology Offerings

 06 Jan 2026 05:40 PM

Biocon: Biocon Biologics Aims To Grow Its Biosimilar Oncology Offerings

Biocon: Company Issues 2 Billion Rupees in Commercial Papers

 02 Jan 2026 05:41 PM

Biocon: Company Issues 2 Billion Rupees in Commercial Papers

Biocon: Company Partners With Ajanta To Market Semaglutide In 26 Nations

 23 Dec 2025 05:52 PM

Biocon: Company Partners With Ajanta To Market Semaglutide In 26 Nations

Biocon: Company Gains Complete Global Rights To Biosimilar Adalimumab By Expanding FKB In-Licensing Deal; Takes Charge Of Manufacturing And Sales; FKB Will Lower Development Expenses And Earn Royalties.

 23 Dec 2025 09:12 AM

Biocon: Company Gains Complete Global Rights To Biosimilar Adalimumab By Expanding FKB In-Licensing Deal; Takes Charge Of Manufacturing And Sales; FKB Will Lower Development Expenses And Earn Royalties.

Biocon: Company Issues Commercial Papers Worth ₹18 Billion

 22 Dec 2025 07:43 PM

Biocon: Company Issues Commercial Papers Worth ₹18 Billion

Biocon: Company Gets EIR With VAI Status From U.S. FDA For New Jersey Facility

 18 Dec 2025 05:51 PM

Biocon: Company Gets EIR With VAI Status From U.S. FDA For New Jersey Facility